PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT00002527: Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed
Official title: Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study
Conditions: Colorectal Cancer
Summary: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of aspirin may be an effective way to prevent the recurrence of polyps in colorectal cancer.
PURPOSE: Randomized phase III trial to study the effectiveness of aspirin in treating patients who have stage I, stage II, or stage III colorectal cancer that has been surgically removed.
Interventions:
name: aspirin
type: Drug
name: placebo
type: Other
Study arms:
design_group_description: 325 mg/day PO
design_group_title: Aspirin
design_group_type: Experimental
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Alliance Foundation Trials LLC
Collaborators: National Cancer Institute
Drug name mappings:
name: 阿司匹林
lang: CN
name: Aspirin
lang: EN
name: サリチル酸
lang: JP
Clinical trial NCT00765817: Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus
Official title: A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications
Conditions: Type 2 Diabetes
Summary: This study will compare the efficacy and safety of exenatide versus placebo in adults whose diabetes is not fully controlled by insulin glargine with or without metformin and/or pioglitazone.
Interventions:
description: subcutaneous injection, twice a day
name: placebo
type: Drug
description: subcutaneous injection, twice a day, 10mcg
name: exenatide
type: Drug
Study arms:
design_group_title: 1
design_group_type: Placebo Comparator
design_group_title: 2
design_group_type: Experimental
Sponsor: AstraZeneca PLC
Collaborators: Eli Lilly & Co.
Drug name mappings:
name: 艾塞那肽
lang: CN
name: Exenatide
lang: EN
name: エキセナチド
lang: JP
Clinical trial NCT04220190: RAPA-501 Therapy for ALS
Official title: Phase 2/3 Trial of Autologous Hybrid TREG/Th2 (RAPA-501) T Stem Cell Therapy for Amyotrophic Lateral Sclerosis
Conditions: Amyotrophic Lateral Sclerosis
Summary: RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Interventions:
description: Experimental: Phase 2/3 Expansion Cohort, Single-agent RAPA-501 T stem cells 80 x 10EE6 cells per infusion (no host conditioning)
name: RAPA-501 Autologous T stem cells
other_name: RAPA-501 cells
type: Biological
Study arms:
design_group_description: Phase 2/3 Expansion Cohort, Single-agent RAPA-501 T stem cells 80 x 10EE6 cells per infusion (no host conditioning)
design_group_title: RAPA-501 Autologous T stem cells
design_group_type: Experimental
Sponsor: Rapa Therapeutics LLC
Collaborators: The General Hospital Corp.
Drug name mappings:
name: RAPA-501
lang: EN
Clinical trial NCT03614494: Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception
Official title: Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception: Randomised Controlled Trial
Conditions: Emergency Contraception
Summary: This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG) co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory conditions. Efficacy will be measured as the percentage of pregnancies prevented.
Interventions:
description: Additional co-treatment
name: Piroxicam 40 mg
type: Drug
description: Standard treatment
name: Levonorgestrel 1.5mg
type: Drug
Study arms:
design_group_description: Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose
design_group_title: Piroxicam
design_group_type: Active Comparator
design_group_description: Placebo (2 tablets) + levonorgestrel 1.5 mg single oral dose
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: The University of Hong Kong
Collaborators: The Family Planning Association of Hong Kong
Drug name mappings:
name: 左炔诺孕酮
lang: CN
name: Levonorgestrel
lang: EN
name: レボノルゲストレル
lang: JP
name: 吡罗昔康
lang: CN
name: Piroxicam
lang: EN
name: ピロキシカム
lang: JP
Clinical trial NCT05313958: Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
Official title: Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children： A Prospective Multicenter Study in South China
Conditions: Leukemia, Monocytic, Acute
Pediatric AML
Summary: This is a multicenter, single arm, prospective, intervention trial. Since cladribine can enhance the biological activity and self-protection of cytarabine, giving cladribine and cytarabine together may kill more cancer cells. 10 centers from South China Childhood Leukaemia Collaborative Group carry out the SCCLG-M5-2022 regimen including two courses of CLAG(cladribine, darubicin and cytarabine) in the induction period for the treatment of newly dignosed acute monocytic leukemia (M5). The targeted drugs sorafenib is used for FLT3 positive acute monocytic leukemia to inhibit the serine / threonine kinase activity of FLT3.
Interventions:
description: 5mg/㎡/day d1-5 in 2 hours, before the use of Cytarabine
name: Cladribine
other_name: cladribine injection
type: Drug
description: 5ug/kg/day d0-5,if Peripheral blood leukocytes<20,000/ul
name: G-CSF
other_name: granulocyte
type: Drug
description: 2g/㎡/day d1-5 in 4 hours, after the use of Cladribine
name: Cytarabine
other_name: Ara-C
type: Drug
description: Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
name: Idarubicin
other_name: IDA
Idamycin
type: Drug
description: Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
name: Mitoxantrone
other_name: MIT
type: Drug
description: 200mg/m2/day was taken orally until molecular biology remission for 2 years
name: Sorafenib
other_name: Nexavar
sorafenib tosylate
sorafinib
type: Drug
Study arms:
design_group_description: The patients in this arm will receive SCCLG-M5 2022 regimen for newly dignosed acute monocytic leukemia (M5) ,including two courses of CLAG(cladribine, darubicin and cytarabine) in the induction period and followed by three courses(HA1M, HA2E, HA3) in consolidation therapy prescribed as the NOPHO-AML 2004 protocol.<br/>The targeted drugs sorafenib 200mg/m2/day orally is used for FLT3 positive acute monocytic leukemia until molecular biology remission for 2 years.
design_group_title: treatment arm
design_group_type: Experimental
Sponsor: Sun Yat-Sen Memorial Hospital
Collaborators: Guangzhou First People's Hospital
Xiangya Hospital Central South University
Foshan Maternity and Child Health Care Hospital
Southern Medical University
The Third Affiliated Hospital, Sun Yat-Sen University
The First Affiliated Hospital of Nanchang University
The First Affiliated Hospital of Guangzhou Medical University
Drug name mappings:
name: 克拉屈滨
lang: CN
name: Cladribine
lang: EN
name: クラドリビン
lang: JP
name: 盐酸米托蒽醌
lang: CN
name: Mitoxantrone Hydrochloride
lang: EN
name: ミトキサントロン塩酸塩
lang: JP
name: 甲苯磺酸索拉非尼
lang: CN
name: Sorafenib Tosylate
lang: EN
name: ソラフェニブトシル酸塩
lang: JP
name: 盐酸伊达比星
lang: CN
name: Idarubicin Hydrochloride
lang: EN
name: イダルビシン塩酸塩
lang: JP
name: 阿糖胞苷
lang: CN
name: Cytarabine
lang: EN
name: シタラビン
lang: JP
Clinical trial NCT04236830: Silver Diamine Fluoride/ Potassium Iodide in Indirect Pulp Capping of Young Permanent Molars
Official title: Effectiveness of Silver Diamine Fluoride/ Potassium Iodide in Indirect Pulp Capping of Young Permanent Molars (a Randomized Controlled Clinical Trial)
Conditions: Tertiary Dentine
Indirect Pulp Capping
Summary: The aim of this study is to evaluate and compare the clinical effectiveness of 38% silver diamine fluoride with and without potassium iodide with that of resin modified glass ionomer cement in indirect pulp capping of young permanent molars.
Interventions:
description: Thirty six first permanent molars will receive 38% SDF/KI as an indirect pulp capping material.
name: Silver diamine fluoride/ potassium iodide
other_name: SDF/KI
type: Drug
description: Thirty six first permanent molars will receive 38% SDF as an indirect pulp capping material.
name: Silver diamine fluoride
other_name: SDF
type: Drug
description: Thirty six first permanent molars will receive RMGIC as an indirect pulp capping material.
name: Resin modified glass ionomer cement
other_name: RMGIC
type: Drug
Study arms:
design_group_description: Riva Star Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia
design_group_title: Silver diamine fluoride/ potassium iodide group
design_group_type: Experimental
design_group_description: Advantage arrest TM, Elevate Oral Care, USA
design_group_title: Silver diamine fluoride group
design_group_type: Experimental
design_group_description: Riva light cure, SDI, Bayswater, Australia
design_group_title: Resin modified glass ionomer cement group
design_group_type: Active Comparator
Sponsor: Alexandria University
Collaborators: Alexandria University
Drug name mappings:
name: 碘化钾
lang: CN
name: Potassium Iodide
lang: EN
name: 银氮烷氟化物
lang: CN
name: Silver Diammine Fluoride
lang: EN
name: フッ化ジアンミン銀
lang: JP
Clinical trial NCT00327444: Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Conditions: Ovarian Neoplasms
Ascites
Summary: This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer.
Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) to placebo treatment on repeat paracentesis in symptomatic malignant ascites in participants with advanced ovarian cancer
Secondary objectives: Safety, tolerability, paracentesis-related parameters, participant-reported outcome.
Interventions:
description: 4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
type: Drug
description: Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
name: Placebo
type: Drug
description: 4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
type: Drug
Study arms:
design_group_description: Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period.<br/>In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study.
design_group_title: Placebo
design_group_type: Placebo Comparator
design_group_description: Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period.<br/>In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study.
design_group_title: Aflibercept
design_group_type: Experimental
Sponsor: Sanofi
Collaborators: Regeneron Pharmaceuticals, Inc.
Drug name mappings:
name: 阿柏西普
lang: CN
name: Aflibercept
lang: EN
name: アフリベルセプト（遺伝子組換え）
lang: JP
Clinical trial NCT00514995: Sodium Oxybate in the Treatment of Binge Eating Disorder
Conditions: Binge Eating Disorder
Summary: The purpose of this research study is to study the effectiveness, tolerability and safety of sodium oxybate in outpatients with binge eating disorder.
Interventions:
description: 4.5 g/night - 9 g/night, liquid taken twice per night
name: Sodium Oxybate
type: Drug
Study arms:
design_group_title: 1
design_group_type: Experimental
Sponsor: The Craig & Frances Lindner Center of Hope
Collaborators: Jazz Pharmaceuticals Plc
Drug name mappings:
name: 羟丁酸钠
lang: CN
name: Sodium Oxybate
lang: EN
Clinical trial NCT04244006: A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
Official title: A Randomized Double-blinded Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
Conditions: Netherton Syndrome
Summary: To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus. They may also use topical corticosteroids or calcineurin inhibitors in case of eczematous lesions. The use of therapies targeting skin inflammation has been reported in a few case reports. Their efficacy is very limited and their uses are limited because of the chronicity of the disease, the impaired skin barrier function and the risk for skin infections and skin cancers. Therefore, there is a huge medical need for novel therapies in NS.The expected consequences of this study are that a 16-week course of dupilumab will be more effective than placebo for the treatment of moderate to severe NS Dupilumab could therefore improve skin condition and quality of life.
Interventions:
description: administration of dupilumab corresponding to dupilumab arm
name: Dupilumab Prefilled Syringe
type: Drug
description: administration of placebo corresponding to placebo arm
name: Placebo Prefilled Syringe
type: Other
Study arms:
design_group_description: The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of Dupilumab 300 mg (syringe of 2 mL for subcutaneous administration).
design_group_title: Dupilumab
design_group_type: Experimental
design_group_description: The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of placebo (syringe of 2 mL for subcutaneous administration)..
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Toulouse University Hospital
Collaborators: Medsharing
Drug name mappings:
name: 度拉糖肽
lang: CN
name: Dulaglutide
lang: EN
name: デュラグルチド（遺伝子組換え）
lang: JP
Clinical trial NCT01662882: A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Official title: An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of Florbetapir (18F) in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Conditions: Alzheimer's Disease
Mild Cognitive Impairment
Summary: Evaluate florbetapir (18F) positron emission tomography (PET) imaging for distinguishing Japanese healthy control subjects, from Japanese subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
Interventions:
description: IV injection, 370 MBq(10mCi), single dose
name: florbetapir (18F)
other_name: 18F-AV-45
Amyvid
Florbetapir F 18
type: Drug
Study arms:
design_group_title: AD Subjects
design_group_type: Experimental
design_group_description: MCI (mild cognitive impairment)
design_group_title: MCI
design_group_type: Experimental
design_group_title: Healthy Controls
design_group_type: Experimental
Sponsor: Avid Radiopharmaceuticals, Inc.
Collaborators: Eli Lilly & Co.
Drug name mappings:
name: 氟贝他吡[18F]
lang: CN
name: Florbetapir F-18
lang: EN
name: フロルベタピル（１８Ｆ）
lang: JP
Clinical trial NCT04098302: Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy
Official title: Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy
Conditions: Alcohol Use Disorder
Summary: The purpose of this study is to evaluate the safety and efficacy of dutasteride in reducing drinking and heavy drinking in men and women with alcohol use disorder. The investigators hypothesize that dutasteride 1 mg per day will be well tolerated in this patient population and that, compared to placebo treatment, dutasteride will result in a greater reduction in drinks per week and in the frequency of heavy drinking days.
Interventions:
description: 1 mg/day oral dutasteride (2 x 0.5 mg capsules)
name: Dutasteride Capsules
other_name: Avodart
type: Drug
description: Placebo capsules with matching appearance as Dutasteride Capsules
name: Placebo Capsules
other_name: inactive placebo
type: Drug
Study arms:
design_group_description: two 0.5 mg capsules of dutasteride daily
design_group_title: dutasteride
design_group_type: Active Comparator
design_group_description: inactive placebo matched in appearance with dutasteride capsules
design_group_title: placebo capsule
design_group_type: Placebo Comparator
Sponsor: University of Connecticut Health Center
Collaborators: National Institute on Alcohol Abuse & Alcoholism
Drug name mappings:
name: 度他雄胺
lang: CN
name: Dutasteride
lang: EN
name: デュタステリド
lang: JP
Clinical trial NCT00296972: Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication
Official title: A Randomized, Multicenter, phaseIIIB, Two Arm Study Evaluating the Tolerability of Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection co-Infected With Human Immunodeficiency Virus Receiving HAART Versus Not Receiving HAART
Conditions: Chronic Hepatitis C
HIV Infections
Summary: The main purpose of this study is to compare the safety, effectiveness and tolerability of using Pegasys with Copegus in people who have both the hepatitis C virus (HCV) genotype 1 and HIV who continue taking HAART (highly active antiretroviral therapy) to those who discontinue taking HAART.
Canadian guidelines recommend that both HIV and HCV should not be treated at the same time as the medications needed to treat these two diseases may interact and that which disease to treat first is dependent on the CD4 count. In this study, the CD4 count must be over 350 cells and one must be stable on HAART before starting the study medication Pegasys in combination with Copegus.
Interventions:
name: peg interferon plus ribavirin
type: Drug
Study arms:
Sponsor: University Health Network
Collaborators: Hoffmann-La Roche, Inc.
Drug name mappings:
name: 培集成干扰素α-2 (北京凯因)
lang: CN
name: Peginterferon Alfacon-2(Beijing Kawin Technology)
lang: EN
name: 利巴韦林
lang: CN
name: Ribavirin
lang: EN
name: リバビリン
lang: JP
Clinical trial NCT03554031: A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome
Official title: A Single Arm, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome
Conditions: Prader-Willi Syndrome
Summary: To evaluate the effectiveness of rhGH (Recombinant human growth hormone) injection for improving motor development in patients with PWS.
Interventions:
description: Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.
name: Recombinant Human Growth Hormone (rhGH) Injection
type: Drug
Study arms:
design_group_description: Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.No control.
design_group_title: rhGH injection/Jintropin AQ
design_group_type: Experimental
Sponsor: Changchun Genescience Pharmaceuticals Co., Ltd.
Collaborators: Tongji Medical College of Huazhong University of Sci & Tech
Peking Union Medical College Hospital
The Children's Hospital of Zhejiang University School of Medicine
Beijing Children Hospital Group Co. Ltd.
Peking University First Hospital
Paediatrics Hospital Affiliated To Fudan University
Drug name mappings:
name: 重组人生长激素(长春金赛)
lang: CN
name: Recombinant human growth hormone(Changchun Genescience)
lang: EN
Clinical trial NCT04496245: Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85
Official title: Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85
Conditions: Respiratory Viral Infection
Covid19
Summary: Parallel group, Wait-list design, with treatment delayed for 3 months. Participants will be randomized on a 1:1 ratio with 500 participants per group in Australia.
Group 1: Wait-list control. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment.
Group 2: Initial treatment. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
Interventions:
description: Broncho-Vaxom adult capsules® (OM85)
name: Broncho-Vaxom®
other_name: OM85
type: Drug
Study arms:
design_group_description: One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment.
design_group_title: Wait-list control
design_group_type: Active Comparator
design_group_description: One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
design_group_title: Initial treatment wtih OM85
design_group_type: Experimental
Sponsor: The University of Queensland
Collaborators: Griffith University
Telethon Kids Institute
The Prince Charles Hospital
Drug name mappings:
name: 细菌溶解产物
lang: CN
name: Bacterial Lysates ( OM Pharma)
lang: EN
Clinical trial NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Official title: A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
Conditions: Small Cell Lung Cancer
Summary: This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Interventions:
description: 12 mg/kg intravenous dose on Day 1 of each 21-day cycle
name: Ifinatamab deruxtecan
other_name: I-DXd
type: Drug
description: Topotecan will be administered per local SoC.
name: Topotecan
type: Drug
description: Amrubicin will be administered per local SoC.
name: Amrubicin
type: Drug
description: Lurbinectedin will be administered per local SoC
name: Lurbinectedin
type: Drug
Study arms:
design_group_description: Participants randomized to receive 12 mg/kg I-DXd monotherapy on Day 1 of each 21-day cycle until unacceptable toxicity, progressive disease (PD), or withdrawal of consent as specified in the protocol.
design_group_title: Ifinatamab deruxtecan (I-DXd)
design_group_type: Experimental
design_group_description: Participants randomized to receive topotecan, lurbinectedin, or amrubicin, as per investigator's choice and per locally approved label (indicated dose and frequency), until a treatment discontinuation criterion is met as specified in the protocol.
design_group_title: Treatment of Physician's Choice (TPC)
design_group_type: Active Comparator
Sponsor: Daiichi Sankyo Co., Ltd.
Collaborators: Merck Sharp & Dohme LLC
Drug name mappings:
name: Ifinatamab deruxtecan
lang: EN
name: イフィナタマブ デルクステカン（遺伝子組換え）
lang: JP